Homrich & Berg Sells 1,125 Shares of Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Homrich & Berg lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 2.9% in the third quarter, HoldingsChannel.com reports. The fund owned 37,793 shares of the company’s stock after selling 1,125 shares during the period. Homrich & Berg’s holdings in Merck & Co., Inc. were worth $3,181,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Nuveen Asset Management LLC lifted its position in Merck & Co., Inc. by 6,517.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock worth $2,038,169,000 after buying an additional 23,940,007 shares during the last quarter. BlackRock Inc. lifted its position in Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after buying an additional 4,397,580 shares during the last quarter. Invesco Ltd. lifted its position in Merck & Co., Inc. by 18.4% in the 2nd quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after buying an additional 2,843,458 shares during the last quarter. Schroder Investment Management Group lifted its position in Merck & Co., Inc. by 67.7% in the 2nd quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock worth $535,075,000 after buying an additional 2,576,060 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in Merck & Co., Inc. by 20.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,661,412 shares of the company’s stock worth $977,809,000 after buying an additional 1,972,587 shares during the last quarter. Hedge funds and other institutional investors own 74.64% of the company’s stock.

Shares of MRK traded up $0.78 during mid-day trading on Tuesday, hitting $84.06. 5,296,561 shares of the company’s stock traded hands, compared to its average volume of 8,931,088. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $87.35. The firm has a market capitalization of $212.82 billion, a P/E ratio of 19.37, a PEG ratio of 1.81 and a beta of 0.54. The business’s 50-day moving average price is $83.95 and its 200-day moving average price is $82.87.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The firm had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. The business’s revenue was up 14.9% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

MRK has been the topic of a number of analyst reports. Argus lifted their price target on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Leerink Swann initiated coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price target on the stock. ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Svb Leerink initiated coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price target on the stock. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Merck & Co., Inc. has a consensus rating of “Buy” and an average target price of $95.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Fundamental Analysis

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amgen, Inc.  Plans Dividend Increase – $1.60 Per Share
Amgen, Inc. Plans Dividend Increase – $1.60 Per Share
Centuria Industrial Reit Declares Interim Dividend of $0.05
Centuria Industrial Reit Declares Interim Dividend of $0.05
Stock Traders Purchase High Volume of Ciena Call Options
Stock Traders Purchase High Volume of Ciena Call Options
TokenPay  Price Down 6% Over Last Week
TokenPay Price Down 6% Over Last Week
Contents Protocol  Reaches 24-Hour Trading Volume of $79,737.00
Contents Protocol Reaches 24-Hour Trading Volume of $79,737.00
0xcert 24 Hour Trading Volume Hits $52,569.00
0xcert 24 Hour Trading Volume Hits $52,569.00


© 2006-2019 Ticker Report